In the phase III METEOR study, cabozantinib demonstrated significantly improved PFS [HR 0.51 (95% CI 0.41–0.62); median 7.4 vs 3.9 months; p < 0.0001], ORR [17% (13–22) vs 3% (2–6); p < 0.0001], and OS [HR 0.66 (0.53–0.83); median 21.4 vs 16.5 months; p = 0.0003] versus everolimus in patients with advanced RCC who had received prior VEGFR-TKI therapy [11]. Here, KDR is linked to renal cell carcinoma.